Skip to main content
SpringerLink
Log in

Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Disturbances in purine metabolism with hyperuricaemia and/or hyperuricosuria are a risk factor in uric acid and Ca oxalate stone formation. By way of a competitive xanthine oxidase inhibition, the formation of uric acid is reduced by allopurinol. In investigations on two groups of patients, MiluritR could be demonstrated to decrease the uric acid levels in serum and urine. No differences could be seen in the dosages of 3×100 mg or 1×300 mg Milurit. Therefore, in stone recurrence prevention, the administration of Milurit 300R is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balogh, A., Fünfstück, R., Traeger, A., Stein, G., Schneider, H.-J.: Untersuchungen zur Kinetik und Wirksamkeit gleicher Dosierungen von Milurit 300R und Milurit 100R.Dtsch. Gesundheitswesen, 1982 (in press).

  2. Backman, U., Danielson, B. G., Fellström, E., Johansson, G., Ljunghall, S., Wikström, B.: Clinical characteristics of the calcium stone disease in hyperuricosuria. In: O. Sperling, W. Vahlensieck (eds): Uric Acid Lithiasis. Steinkopff Verlag, Darmstadt 1981, pp. 106–109.

    Google Scholar 

  3. Barsotti, G., Vagelli, G., Cristofono, C., Niosi, F., Giovannetti, S.: The uric acid and urinary glycosaminoglycans (GAGs) excretion in normal subjects and in patients with calcium stone disease. 2nd Int. Symp. on Advances in Metabolic Physicochemical and Therapeutical Aspects of Urolithiasis. Turin 1981.

  4. Berg, W., Gutsche, B., Schäfer, F., Beck, G.: Eine modifizierte Methode zur quantitativen Oxalsäurebestimmung im Harn.Z. Urol. Nephrol., 72, 323 (1979).

    Google Scholar 

  5. Bresnik, W., Heiter, H., Merz, D. P., Holler, H. D., Lang, P. D., Vollmar, J.: Vergleich der harnsäuresenkenden Wirkung von 300 mg Allopurinol bei einmaliger und fraktionierter Gabe.Therapiewoche, 25, 4862 (1975).

    Google Scholar 

  6. Finlayson, B.: Die derzeitigen Vorstellungen über die Urolithiasis.Excerpta Urol., 4, 13 (1981).

    Google Scholar 

  7. Hesse, A., Schneeberger, W., Bach, D., Dewes, W., Vahlensieck, W.: Latent hyperuricemia and hyperuricosuria — a risk factor for stone formation — diagnosis with a purine loading test. In: O. Sperling, W. Vahlensieck (eds): Uric Acid Lithiasis. Steinkopff Verlag, Darmstadt 1981, pp. 81–87.

    Google Scholar 

  8. Green, M. L., Fujimoto, W. Y., Seegmiller, J. E.: Urinary xanthin stone — a rare complication of allopurinol therapy.N. Engl. J. Med., 280, 426 (1969).

    Google Scholar 

  9. Hande, K., Reed, E., Chabner, B.: Allopurinol kinetics,Clin. Pharmacol. Therap., 23, 598–600 (1978).

    Google Scholar 

  10. Jong Go, Kim: Das Harnsäuresteinleiden, seine Ätiologie und Pathogenese. Med. Dissertat., Jena 1981.

  11. Joost, J., Egger, G., Hohlbrügger, G., Marberger, H.: Epidemiologie des Nierensteinleidens in Tirol.Öst. Ärztetg., 35, 10 (1980).

    Google Scholar 

  12. Lach, H.-J., Bader, B., Schmitker, J., Li, E. H.: Pharmakokinetische Untersuchungen zur Plasma-Eliminationshalbwertzeit von Oxipurinol.Arzneim. Forsch., 32, 76 (1982).

    Google Scholar 

  13. Landgrebe, A. R., Nyhan, W. L., Coleman, M.: Urinary tract stones resulting from the excretion of oxypurinolN. Engl. J. Med., 292, 629 (1975).

    Google Scholar 

  14. May, P., Vahlensieck, W., Bach, D.: Therapie des Harnsäuresteinleidens. In: W. Vahlensieck (ed.): Der Harnsäure-, Zystin-, Xanthinstein. Springer Verlag, Berlin-Heidelberg-New York 1980, pp. 23–38.

    Google Scholar 

  15. Mayer, E., Stockhausen, G.: Therapiestudie mit einmal täglicher Gabe von Zyloric 300.Therapiewoche, 25, 4627 (1975).

    Google Scholar 

  16. Resnick, M. J., Rush, W. H., Boyce, W. H.: Metabolische Störungen und ihre Ursachen bei der Steinbildung.Excerpta Urol., 4, 33 (1981).

    Google Scholar 

  17. Robertson, W. G., Peacock, M., Heyburn, P. J., Marshall, D. H., Clark, P. B.: Risk factors in calcium stone disease of the urinary tract.Br. J. Urol., 50, 449 (1978).

    Google Scholar 

  18. Schneider, H.-J.: Möglichkeiten der Harnsteinprophylaxe.Z. Aerztl. Fortbild., 72, 1164 (1979).

    Google Scholar 

  19. Schneider, H.-J.: Epidemiologische Aspekte der Urolithiasis.Urologe [B],19, 54 (1979).

    Google Scholar 

  20. Schneider, H.-J.: Ätiologie und Pathogenese der Urolithiasis.Urologe [A],19, 195 (1980).

    Google Scholar 

  21. Tiselius, H.-G., Larson, L.: Urine composition in patients with renal stone disease during treatment with allopurinol.Scand. J. Urol. Nephrol., 14, 65 (1980).

    Google Scholar 

  22. Tjsi-Fan Yu: Urolithiasis in hyperuricemia and gout.J. Urol., 126, 424 (1981).

    Google Scholar 

  23. Vahlensieck, W.: Epidemiologie und Pathogenese des Harnsteinleidens.Dtsch. Med. Wochenschr., 105, 799 (1980).

    Google Scholar 

  24. Zechner, O., Latal, D.: Die Problematik der Harnsteinrezidivprophylaxe.Acta Urol. Belg., 12, 103 (1981).

    Google Scholar 

  25. Zechner, O., Pflüger, H.: Oral purine loading for evaluation of uric acid excretion in patients with urinary stones.Invest. Urol., 18, 115 (1980).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urological Clinic and OPD, Friedrich Schiller University, Jena, GDR

    H. -J. Schneider & P. Brundig

  2. Institute of Pharmacology and Toxicology, Friedrich Schiller University, Jena, GDR

    A. Balogh & A. Traeger

  3. Clinic of Internal Medicine, Friedrich Schiller University, Jena, GDR

    G. Stein & R. Fünfstück

Authors
  1. H. -J. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Brundig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Balogh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Traeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Fünfstück
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, H.J., Brundig, P., Balogh, A. et al. Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300. International Urology and Nephrology 15, 121–129 (1983). https://doi.org/10.1007/BF02085441

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02085441

Keywords

Search

Navigation